Litigation Details for Skandia Mutual Life Insurance Co. v. Viatris Inc. (S.D.N.Y. 2021)
✉ Email this page to a colleague
Skandia Mutual Life Insurance Co. v. Viatris Inc. (S.D.N.Y. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-02-15 |
| Court | District Court, S.D. New York | Date Terminated | |
| Cause | 15:78j(b)ss Stockholder Suit | Assigned To | |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 7,449,012; 7,794,432; 8,048,035; 8,870,827 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Skandia Mutual Life Insurance Co. v. Viatris Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Skandia Mutual Life Insurance Co. v. Viatris Inc. (S.D.N.Y. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2021-02-14 | 1 | Complaint | expiration of U.S. Patent Nos. 7,449,012 B2 (the “’012 patent”) and 7,794,432 B2 (the “’432 patent”), which expire…Numbers 7,449,012, 7,794,432, 8,048,035, and 8,870,827 (the “EpiPen Patents”). These four patents have a priority…) in 2007. There are numerous patents covering the EpiPen. These patents do not expire until September…additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent Numbers …The issuance of the EpiPen Patents, and Mylan’s designation of these patents as covering the EpiPen, further | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
